|
Delayed
Nasdaq
03:17:04 30/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 2.280 USD | -3.80% |
|
-16.18% | -74.24% |
Company Valuation: Atossa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 202.6 | 66.92 | 110.3 | 118.8 | 76.21 | 23.65 | - | - |
| Change | - | -66.97% | 64.77% | 7.71% | -35.83% | -68.97% | - | - |
| Enterprise Value (EV) | 202.6 | 66.92 | 110.3 | 118.8 | 76.21 | 23.65 | 23.65 | 23.65 |
| Change | - | -66.97% | 64.77% | 7.71% | -35.83% | -68.97% | 0% | 0% |
| P/E | -8.89x | -2.52x | -3.67x | -4.72x | -2.19x | -0.63x | -0.85x | 0.87x |
| PBR | 1.47x | 0.57x | 1.22x | 1.69x | 1.92x | - | - | - |
| PEG | - | -0.2x | -0.3x | 0.3x | -0.1x | 0.09x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 0.2x |
| EV / Revenue | - | - | - | - | - | - | - | 0.2x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.65x | -0.62x | 0.48x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.7 | -3.15 | -3.6 | -3 | -4.04 | -3.747 | -2.783 | 2.715 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 118.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.52 | -27.69 | -31.38 | -27.62 | -37.14 | -36.12 | -38.03 | 49.46 |
| Net income 1 | -20.61 | -26.96 | -30.09 | -25.5 | -34.77 | -35.3 | -38.03 | 49.46 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 24.000 | 7.927 | 13.200 | 14.161 | 8.850 | 2.370 | 2.370 | 2.370 |
| Nbr of stocks (in thousands) | 8,442 | 8,442 | 8,354 | 8,387 | 8,611 | 9,979 | - | - |
| Announcement Date | 28/2/22 | 22/3/23 | 1/4/24 | 25/3/25 | 25/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.63x | - | - | - | 23.65M | |
| 16.92x | 6.39x | 12.26x | 1.77% | 64.14B | |
| 30.57x | 8.11x | 26.59x | 0.05% | 55.53B | |
| 36.68x | 6.52x | 19.45x | 0.88% | 53.03B | |
| 35.39x | 3.41x | 14.74x | -.--% | 45.99B | |
| 49.25x | 5.68x | 31.09x | -.--% | 42.45B | |
| -19.59x | 189.6x | -20.86x | -.--% | 40.45B | |
| 31.7x | 8.06x | 20.96x | 0.41% | 32.25B | |
| 47.12x | 8.37x | 28.08x | -.--% | 34.47B | |
| 27.96x | 5.9x | 15.29x | -.--% | 24.23B | |
| Average | 25.54x | 26.89x | 16.40x | 0.34% | 39.26B | |
| Weighted average by Cap. | 27.96x | 25.38x | 16.46x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ATOS Stock
- Valuation Atossa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
